Reading this on a mobile device? Try our optimized mobile version here:

March 5, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • FDA OKs expanded use of CSL Behring's Corifact
    The FDA has approved the use of CSL Behring's Corifact to address surgical bleeding in children and adults with inherited factor XIII deficiency, which leads to bleeding risk due to unstable clots. About 150 people in the U.S. have the condition. The drug has been approved since 2011 for use in routine preventive treatment for patients with the congenital deficiency. The intravenous infusion treatment is administered roughly each month. American City Business Journals/Philadelphia (3/1) LinkedInFacebookTwitterEmail this Story
Complimentary Webinar -
Global Change Control: Managing Change as a Best Practice, Not Just Compliance

Attend this webinar to better understand the differences as well as the integration points between change control and document management, and how integrating these processes can result in a more efficient quality system.
Tuesday, March 19 @ 2pm Eastern
Register Now.
  Health Care & Policy 
  • EU approves Roche's Perjeta for metastatic breast cancer
    The European Medicines Agency OK'd Roche Holding's Perjeta, or pertuzumab, in combination with trastuzumab and docetaxel, to treat women with previously untreated HER2-positive metastatic breast cancer. The approval followed the release of data from a late-stage trial, which showed that patients who took a combination of Perjeta, trastuzumab and chemotherapy survived 6.1 months longer without their disease progressing than those who received trastuzumab and chemotherapy. Fox Business/Dow Jones Newswires (3/5) LinkedInFacebookTwitterEmail this Story
Reach Biopharmaceutical Decision-Makers with SmartBrief
You read SmartBrief, but did you know that SmartBrief publishes more than 30 unique e-newsletters for life science and health care professionals? SmartBrief delivers an engaged audience of more than a half-million business leaders, driving best-in-class click through rates and consistent reader engagement. Find out if we're reaching your target audience or contact us.
  Company & Financial News 
  Global Developments 
  • Europe supports push to cure rare conditions
    The European Commission will spend about $187 million on 26 research projects on rare diseases, involving research teams from 29 countries. The goal is to discover effective treatments for a metabolic, immune and cardiovascular disorders, among others. PharmaTimes (U.K.) (3/1) LinkedInFacebookTwitterEmail this Story

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or 

  Food & Agriculture 
  • Limits on biotechnology impede Australia's productivity
    Australia's broadacre productivity growth dropped from 1.8% to 0.2% over 15 years partly due to the country's slow adoption of agriculture biotechnology, said Paul Morris, executive director of the Australian Bureau of Agriculture and Resource Economics and Sciences. "The state moratoriums in Australia have slowed the adoption by farmers and possibly the development of new varities," Morris said. The Weekly Times (Australia) (3/5) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Exec predicts cellulosic biofuel production to boom in 2015
    The CEO of the company that operates a commercial-scale cellulosic ethanol plant in Crescentino, Italy, believes 2013 will be a turning point for the industry, with about 30 million gallons of cellulosic biofuel being produced in the U.S. and Europe. By the end of 2014, global output could reach 100 million gallons, said Guido Ghisolfi, CEO of Beta Renewables. "The boom year will be 2015 with 15 to 20 plants producing hundreds of millions of gallons," Ghisolfi said. Reuters (3/4) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

Concentrate all your thoughts upon the work at hand. The sun's rays do not burn until brought to a focus."
--Alexander Graham Bell,
Scottish-born American inventor

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information